Boston Scientific Archives - Page 6 of 19

Boston Scientific to acquire Apollo Endosurgery for more than $600M

Boston Scientific (NYSE:BSX) today announced it entered a definitive agreement to acquire Apollo Endosurgery (NSDQ:APEN) for more than $600 million.

The Marlborough, Massachusetts-based company will acquire the endoluminal surgical device maker for a cash price of $10 per share to reflect an enterprise value of approximately $615 million.

Apollo Endosurgery’s product portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss. ELS procedures are a less-invasive alternative to open and laparoscopic surgery for patients with diseases in the gastrointestinal tract or morbid obesity. It also provides a quicker recovery to minimize the risks of surgical complications.

“Endoluminal surgery is an emerging field and a core focus for our Endoscopy business,” Mike Jones, senior VP and president of endoscopy at Boston Scientific, said in…

Data backs Boston Scientific Acurate neo2 aortic valve

Acurate Neo2 [Image from Boston Scientific]Boston Scientific (NYSE:BSX) announced positive results from its post-market clinical follow-up study for the Acurate neo2 aortic valve system.

Marlborough, Massachusetts-based Boston Scientific’s findings included a high procedural success rate of 98.4%. The study observed low rates of mortality and paravalvular leak (PVL).

Findings, presented at PCR London Valves 2022, simultaneously published in EuroIntervention, according to a news release.

The European study included a primary safety endpoint of all-cause mortality set at 0.8% at 30 days. Data also demonstrated that no patients experienced greater than moderate PVL. It found that 1.9% experienced moderate PVL and 18.9% experienced mild PVL. Other findings included a low 6.5% rate of new pacemaker implantation at 30 days post-procedure. Boston Scientific’s device demonstrated no incidence of disabling stroke or acute kidney injury.

“Wit…

Why are so many medical device companies making big investments in Ireland?

[Image from Ainars Djatlevskis on Unsplash] The foreign direct investment agency for Ireland has some of the biggest names in medtech investing in the country.

Within recent years, a number of major medtech companies celebrated anniversaries. Abbott’s was 70 years, Medtronic’s was 40 and Boston Scientific’s was 25.

That’s how long those companies have operated in Ireland.

Gerard Kilcommins, Medtronic VP of global manufacturing, vascular therapies and implants and country director in Ireland, said in a report earlier this year that its 40-year anniversary represents “an important milestone” in the company’s history.

“Our sites in Ireland have played a significant role in Medtronic’s evolution from medical device manufacturer to a global leader in healthcare technology,” Kilcommins said in July.

Each of those three companies, plus many more big names in medtech, choose Ireland for a broad range of inve…

Boston Scientific reports mixed Q3 results amid challenging economic environment

Boston Scientific (NYSE: BSX) today reported third-quarter revenue that beat the consensus forecast on Wall Street, but it missed by a penny on earnings.

The Marlborough, Massachusetts–based interventional medical devices giant also reduced its full-year adjusted EPS outlook amid a challenging macroeconomic environment. A host of medical device companies are facing the effects of a strong dollar and continued supply chain problems.

Truist analysts described Boston Scientific’s revenue beat as very impressive. But when it came to the reduced EPS outlooks, they were somewhat disappointed. “We would have thought BSX might be a bit better-positioned-than-peers to absorb [foreign exchange] EPS headwinds on the bottom line,” said Richard Newitter and other analysts at Truist.

Investors reacted by sending BSX shares up more than 2% to $42.24 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the worldR…

Boston Scientific veteran is joining Getinge

Joanna Engelke, Getinge’s incoming EVP of quality compliance, regulatory & medical affairs [Image courtesy of Engelke]Getinge today announced a new EVP of quality compliance, regulatory & medical affairs.

Joanna Engelke will also join the Gothenburg, Sweden–based company’s executive team. Her experience includes a decade at Boston Scientific, with her final four years spent as the company’s SVP of global quality and regulatory.

Engelke most recently was chief quality officer at the electronic cigarette company Juul Labs. The FDA in June ordered the company to stop selling its e-cigarettes.

Getinge said Engelke will join the company on Oct. 6. She replaces Lena Hagman, who has decided to leave the company.

More about Getinge

Getinge provides a wide range of products and services to hospitals and life science researchers. It employs more than 10,000 people in 38 countries.

The COVID-19 pandemic had a major impact on thi…

4 major cardiology trends you need to know from TCT 2022

Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive.

The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations.

Medtronic, Abbott, Edwards and Boston Scientific represent a few of the companies revealing new data for their cardiovascular offerings. ReCor Medical, Abiomed and more got involved, too.

Plenty of the study outcomes represented positive steps forward, while other companies hit speed bumps in their efforts. Here are some of the biggest takeaways from the conference:

1. Renal denervation innovations plug along

Medtronic (NYSE:MDT) announced study data that demonstrates significant blood pressure reduction with the Symplicity renal denervation system.

The RDN minimally invasive procedure delivers radiofrequency energy to specific nerves near the …

Boston Scientific names Kathryn Unger as VP of environmental, social and governance

Boston Scientific (NYSE:BSX) today announced it appointed Kathryn Unger as VP of environmental, social and governance (ESG).

In this role, Unger will lead the company’s global ESG council that comprises subject matter experts from across the company to provide updates to the Marlborough, Massachusetts-based company’s board of directors. The framework of the initiative is intended to create shared accountability for ESG progress.

““ESG is an important part of our enterprise strategy, and we have been steadily increasing our focus on improving our practices, reporting strategies and organizational talent,” said Meghan Scanlon, senior vice president and president of urology and pelvic health and executive sponsor for ESG at the company. “The breadth and depth of Kathryn’s experiences and expertise equip her to lead our global organization in the next phase of our ESG evolution.”

Boston Scientific employs more than 41,000 people across 115 …

Boston Scientific Sentinel cerebral protection system does not meet primary endpoint

[Image from Boston Scientific]Boston Scientific (NYSE:BSX) announced that its PROTECTED TAVR clinical trial evaluating its Sentinel system missed its primary endpoint.

Marlborough, Massachusetts-based Boston Scientific designed the Sentinel cerebral protection system to capture and remove embolic debris stemming from transcatheter aortic valve replacement (TAVR). The goal is to extract the debris before it can reach the brain and potentially cause a stroke. Sentinel provides cerebral embolic protection (CEP) during TAVR.

PROTECTED TAVR evaluated periprocedural stroke reduction and neurologic outcomes in patients with aortic stenosis treated with either Sentinel during TAVR or TAVR alone. It did not meet its primary endpoint. Data demonstrated a non-significant trend toward a lower rate of stroke in patients treated with the Sentinel device. The study demonstrated a 21% relative risk reduction in all stroke through 72 hours or time of hospital discharge (2.3% with …

Abbott says study backs Amplatzer Amulet against Boston Scientific’s Watchman

Left atrial appendage occlusion (LAAO) devices on the market include Abbott’s Amplatzer Amulet (left) and Boston Scientific’s Watchman (right). [Images courtesy of Abbott and Boston Scientific]Abbott’s (NYSE:ABT) today presented data supporting the use of its Amplatzer Amulet against Boston Scientific’s (NYSE:BSX) competing device.

Device-related factors and all-cause death represented categories favoring Amplatzer Amulet against Watchman, according to a news release.

Abbott designed its Amplatzer Amulet left atrial appendage (LAA) occluder with dual-seal technology. It features a lobe or piece to fill the cavity of the LAA and a disc to close off the opening into the LAA. The company said it is the first and only minimally invasive treatment option to offer immediate and complete dual-sealing closure of the LAA. It reduces the risk of stroke and eliminates the need for blood-thinning medication.

The prospective, international, multi-center Amul…

The 10 largest medtech employers — and what their employees really think

Employees of the 10 largest medtech employers are happy to be a part of a company that is having a positive impact on patient populations.

That was one major takeaway as MassDevice compiled some current and former employee reviews posted on Glassdoor.

Medtronic, Philips and Johnson & Johnson MedTech top the list of largest medtech employers. The 10 companies we looked at were the largest employers in Medical Design & Outsourcing‘s newest Big 100 report on the largest medical device companies.

Company Employees Medtronic 95,000 Philips 78,189 Johnson & Johnson MedTech 75,000

As with most companies, there are some qualms with corporate bureaucracy and reorganizations creating frustration for employees.

Employment in the medtech industry is on the rise, according to a recent analysis of our Medtech Big 100 data. There were 1,268,924 employees among the 100 largest companies that report human capital in their annual repor…

FDA approves expanded label for Boston Scientific Watchman FLX

The Watchman FLX [Image from Boston Scientific]Boston Scientific (NYSE:BSX) announced today that the FDA approved expanded labeling for its Watchman FLX LAAC device for stroke prevention.

The approval includes labeling with a 45-day dual anti-platelet therapy (DAPT) option for the left atrial appendage closure device (LAAC). DAPT represents an alternative to 45-day oral anticoagulation (OAC) plus aspirin for post-procedural treatment of non-valvular atrial fibrillation (NVAF) patients.

Dr. Ian Meredith, global CMO for Boston Scientific, said in a news release that the approval represents a significant step forward. “This revised labeling provides physicians more flexibility to exercise their clinical judgment based on individual patient characteristics to determine the most appropriate post-procedural antithrombotic medication regimen.”

Meredith added that the legacy Watchman and current-generation Watchman FLX tech’s robust safety and eff…

Boston Scientific to pay Nevro $85M to settle rest of patent litigation

Nevro (NYSE:NVRO) and Boston Scientific (NYSE:BSX) announced today that they reached a settlement over intellectual property litigations.

The settlement gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, with Nevro given the freedom to operate using the features and capabilities in its current line of products. It concludes all existing litigations between the companies and includes a payment of $85 million from Boston Scientific to Nevro.

Nevro had filed a patent infringement suit in the Northern District of California relating to high-frequency paresthesia-free spinal cord stimulation (SCS) therapy. In 2018, Boston Scientific assured the court that it had no imminent plans to commercially launch a high-frequency spinal cord stimulation system delivering therapy at frequencies between 1,500 Hz and 100 kHz and the parties agreed to the dismissal of Nevro’s d…